Related Experiment Video

Updated: Jun 1, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Leukemia-associated antigens are immunogenic and have prognostic value in acute myeloid leukemia

Lu Zhang, Jochen Greiner

    Immunotherapy
    |June 15, 2011
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
    05:24

    Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

    Published on: February 21, 2021

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Related Experiment Videos

    Last Updated: Jun 1, 2026

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
    09:01

    Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

    Published on: March 26, 2018

    Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
    05:24

    Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia

    Published on: February 21, 2021

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    Related Concept Videos

    Disorders of Leukocytes01:27

    Disorders of Leukocytes

    Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
    Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
    Antigens Involved in Adaptive Immunity01:26

    Antigens Involved in Adaptive Immunity

    An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
    Complete Antigens
    Complete antigens possess both immunogenicity and reactivity.

    Articles linked to this work by shared authors, journal, and citation graph.

    Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer.

    Scientific reports·2026

    Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia.

    Leukemia·2025

    Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.

    EBioMedicine·2025

    Atacama Large Aperture Submillimeter Telescope (AtLAST) science: Probing the transient and time-variable sky.

    Open research Europe·2025

    Immunotherapeutic Potential of Mutated NPM1 for the Treatment of Acute Myeloid Leukemia.

    Cancers·2024

    The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

    Leukemia·2024

    Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis.

    Immunotherapy·2026

    From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies.

    Immunotherapy·2026

    In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more.

    Immunotherapy·2026

    Bromodomain inhibitors in autoimmune diseases.

    Immunotherapy·2026

    Cancer vaccines as targeted therapies: translational advances and challenges.

    Immunotherapy·2026

    Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma.

    Immunotherapy·2026

    Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database.

    Frontiers in medicine·2026

    Leucine-rich alpha-2 glycoprotein as a predictor of primary non-response to anti-TNF-α therapy in biologic-naïve Egyptian IBD patients.

    BMC gastroenterology·2026

    Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

    MedScience·2026

    Anxiety and mood disorders are associated with greater healthcare and procedural utilization in idiopathic intracranial hypertension.

    Journal of neurointerventional surgery·2026

    sFgl2‑enriched MSC-EVs attenuate colitis by enhancing immunoregulatory capacity.

    Colloids and surfaces. B, Biointerfaces·2026

    Patterns and outcomes of emergency department visits by patients receiving immune checkpoint inhibitors: a single-center, retrospective study.

    Cancer treatment and research communications·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us